Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ablation as First-line Therapy for Atrial Fibrillation.
Author(s): Jason G Andrade Added: 1 year ago

Electrophysiology & Arrhythmia
SK Channels as a New AAD Target
Author(s): Arnela Saljic , Jordi Heijman , Dobromir Dobrev Added: 6 months ago

Electrophysiology & Arrhythmia
Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy
Author(s): James Burton , Clara Bonanad Lozano , Aaron Wong , et al Start date: Jul 02, 2025
.img-row:after { content: ""; clear: both; display: table; } .img-column { float: left; width: 50%; padding: 5px; } @media screen and (max-width: 500px) { .img-column { width: 100%; } } Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)… View more

Cardiovascular Renal Metabolic

Heart Failure
Advancements in Triglyceride-lowering Therapies
Author(s): , Added: 10 months ago
In this video series, recorded at ESC 2024 in London, Prof Gerald Watts (University of Western Australia, Perth, Australia) is joined by Prof Robert S Rosenson (Mount Sinai Icahn School of Medicine, New York, US) to discuss developments in triglyceride-lowering therapies.The faculty consider triglycerides as a risk factor for cardiovascular disease and explore the relationship between… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Tricuspid Regurgitation Therapy
Author(s): Qiuyu Martin Zhu , Natalia Berry Added: 1 year ago

Heart Failure
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 1 month ago

Anticoagulation

Prevention & Chronic Conditions
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 11 months ago

COVID-19

CV Disease in Special Populations
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 3 months ago

CV Disease in Special Populations

Heart Failure
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 3 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 3 months ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure